Welcome to the community of next.
From our global vantage point we’re witnessing an extraordinary transformation – to deliver meaningful medical technology breakthroughs that improve the way we diagnose and treat disease.
We’re solving a new equation for human health, uniting the extensive capabilities of a global conglomerate. Collectively, we’ve designed our products to improve surgical procedures, expand vascular interventions, and advance minimally-invasive medicine. The pursuit of possibility through therapeutic innovation energizes and inspires us every day. And the urgency to help our customers improve patient outcomes compels us to find what’s next.
Through continuous innovation, MicroPort® is leading the way in cardiovascular therapeutic solutions. We remain dedicated to providing advanced minimally invasive therapies for structural heart diseases. Our Firehawk® - the Target Eluting Stent - now sets industry standards, and our Transcatheter Aortic Valve Replacement solution - Vitaflow® - is currently expanding across the globe.
We have extensive experience and 20 years of superior clinical results in orthopedics. The MicroPort® Evolution® medial-pivot Knee System is uniquely engineered to reproduce a healthy knee’s stability and motion, and boasts 95% patient satisfaction1.
With a complete focus on rapid recovery surgical approaches for hip replacements and continuous partnership with pioneering surgeons we’ve developed a number of tissue-sparing surgical hip approaches. We’re proud to say that our patients have stayed in the hospital for a shorter amount of time, been discharged directly to their home more often, and are less likely to return within 30 days for any reason2-4.
Cardiac Rhythm Management
MicroPort® CRM is a pioneering company in the physiological management of heart disease using high-tech implantable devices and diagnostic solutions. With dedicated R&D teams and state-of-the-art manufacturing facilities, MicroPort® CRM designs, develops, and markets solutions for the management of heart rhythm disorders, such as implantable pacemakers and defibrillators, as well as heart failure with cardiac resynchronization therapy (CRT), worldwide. The company is headquartered in Clamart (outside Paris, France), and our world-class technologies are manufactured in France, Italy, the Dominican Republic and China for the Chinese market.
MicroPort® has achieved several firsts and won numerous awards in recognition of its high-tech research, patent registration and advanced capabilities within the electrophysiology field. Columbus® is the first 3D EP navigation system featuring real time magnetic device tracking with cardiac motion compensation, and FireMagic® is the first 3D Irrigated Ablation Catheter.
With several large-scale education programs to empower physicians and increase the effective treatment rates of arrhythmia patients, and in the process, reduced the burden on healthcare systems and society.
MicroPort® is committed to providing personalized treatment programs and services to patients with aortic and peripheral diseases. Through continuous innovation we provide doctors with medical solutions that save, or make a real difference to the quality of patients’ lives. MicroPort®’s CASTOR® is the world's first branched aortic stent for clinical application and offers a safe and convenient method to reconstruct the left subclavian artery.
We are continuously collaborating with medical professionals and experts across the globe to bring the latest technologies and innovation to new therapies for neurovascular intervention. Our TWIN (Tubridge & Willis) solutions offer surgeons complete tool sets for resolving potential issues during hemorrhagic stroke. Through minimally invasive means, surgeons can perform both rapid repair of ruptured blood vessel walls through stent grafts, and isolation of aneurysm through blood flow redirection devices.
Our innovative robots offer surgeons superior surgical outputs. Honghu Orthopedic surgery navigation and positioning system is a one-of-a-kind surgical robotic product for Total Knee Arthroplasty (TKA) helping orthopedic surgeons resolve issues faced during traditional surgery and achieve higher accuracy and efficiency. Ultimately, Honghu reduces trauma and bleeding for patients during surgery, and enables a faster recovery process post operation. In addition, our Toumai™ Endoscopic Surgery Robot successfully completed its First-In-Man (FIM) trial for Robot Assisted Laparoscopic Radical Prostatectomy (RALRP) on November 1st, 2019.
MicroPort® is also active in various other fields such as diabetes, having developed the La Fenice® Insulin pump and the Hypophyseal Hormone Infusion pump - a 'high tech' needle and syringe containing a supply of GnRH.
In the field of interventional technology we’ve developed the KW membrane oxygenator, used to add oxygen to, and remove carbon dioxide from the blood.
The Evermend™ VSD occluders are designed for the percutaneous, transcatheter occlusion of ventricular septal defects (VSD).
MicroPort®’s DynBite® is an ideal rehabilitation tool for clinicians and therapists, utilizing dynamic draft technology to treat jaw opening limitation due to muscle injuries, surgeries, tumor radiation therapies, osteoarthritis, temporomandibular joint dysfunctions, post-infection or post-traumatic causes.
In reproductive health, our Lotus™ ovum aspiration needle’s unique humanized design obtains the highest quality eggs in the safest possible way, improving operative success rate and the comfort of operators, and reducing the trauma of ovarian puncture to the patient.